We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Staphylococcus Aureus Bacteraemia in Adults (ISAC)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2014 by Achim Kaasch, University of Cologne.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT02098850
First Posted: March 28, 2014
Last Update Posted: December 3, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Achim Kaasch, University of Cologne
  Purpose
The purpose of this evaluation is to record the management and outcome of adults with S.aureus bacteraemia (SAB) across multiple European, Asian and North American sites and to identify key quality indicators associated with improved outcome.

Condition
Staphylococcus Aureus Bacteremia

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 3 Months
Official Title: A Prospective International Study of Staphylococcus Aureus Bacteraemia in Adults by the International Staphylococcus Aureus Collaboration

Resource links provided by NLM:


Further study details as provided by Achim Kaasch, University of Cologne:

Primary Outcome Measures:
  • Mortality [ Time Frame: 90 Days ]

Secondary Outcome Measures:
  • Length of hospital stay [ Time Frame: 90 Days ]

Estimated Enrollment: 2000
Study Start Date: January 2013
Estimated Study Completion Date: May 2016
Estimated Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Detailed Description:

Staphylococcus aureus (S. aureus) is one of the most common causes of bloodstream infections. Associated mortality has been reported to vary widely (4%-40%) although no obvious explanation for such variation has been identified.

Despite the existence of clinical guidelines, there is considerable variation in the management of S.aureus bacteraemia (SAB) between centres. Part of the variation in clinical management is due to the limited evidence base defining optimal therapy. Fewer than 1500 patients have been recruited to randomised controlled trials in the past 40 years; practice is therefore based largely on experience and observational studies.

The purpose of this evaluation is to record the management and outcome of adults with SAB across multiple European, Asian and North American sites. We aim to establish a broader knowledge base, identify key quality indicators associated with improved outcomes, and to provide comparator data to ensure that patients enrolled in randomized controlled trials are representative of bacteraemic S. aureus patients as a whole. All participating centres are experienced in the management of S. aureus bacteraemia and in conducting evaluations of current management practice and outcomes from S. aureus bacteraemia. Data is checked for plausibility by a centralized data quality control group.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patient in tertiary care hospitals
Criteria

Inclusion Criteria:

  • S. aureus (methicillin sensitive or resistant) isolated from one or more blood cultures

Exclusion Criteria:

  • Recurrent episodes of S. aureus bloodstream infection
  • Polymicrobial infection
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02098850


Contacts
Contact: Achim J Kaasch, MD +4922147832100
Contact: Christian M Bernasch

Locations
Germany
Uniklinik Koln Recruiting
Cologne, NRW, Germany, 50935
Contact: Achim J Kaasch, MD    +4922147832022    achim.kaasch@uk-koeln.de   
Principal Investigator: Achim J Kaasch, MD         
Uniklinik Freiburg Recruiting
Freiburg, Germany, 79106
Contact: Siegbert Rieg, MD         
Univeritatklinikum Schleswig-Holstein Recruiting
Lübeck, Germany, 23562
Contact: Jan Rupp, MD         
Korea, Republic of
Seoul National University Bundang Hospital Recruiting
Seoul, Korea, Republic of
Contact: Hong Bin Kim         
Spain
Hospital San Pau Recruiting
Barcelona, Spain, 08026
Contact: Mercedes Gurgui Ferrer, MD         
University Hospital Clinic de Barcelona Recruiting
Barcelona, Spain, 08028
Contact: Alex Soriano, MD         
Hospital Vall d'Hebron Recruiting
Barcelona, Spain, 08035
Contact: Benito Almirante, MD         
Hospital Universitario Son Espases Recruiting
Palma. Mallorca, Spain, 79 07120
Contact: Jose Luis Perez Saenz, MD         
Salamanca Hospital Recruiting
Salamanca, Spain
Contact: Hugo Guillermo Ternavasio-de la Vega, MD         
Hospital Universitario Virgen Macarena Recruiting
Sevilla, Spain, 41007
Contact: Jesus Rodriguez-Bano, MD         
Hospital Universitario Virgen del Rocio Recruiting
Sevilla, Spain, 41013
Contact: Luis Edwardo Lopez-Cortes, MD         
Taiwan
Far Eastern Memorial Hospital Recruiting
New Taipei City, Taiwan
Contact: Chun-Hsing Liao         
United Kingdom
Birmingham Heartlands Hospital Recruiting
Birmingham, West Midlands, United Kingdom, B9 5SS
Contact: Das Pillay, MD         
Brighton and Sussex University Hospitals Recruiting
Brighton, United Kingdom, BN2 5BE
Contact: Martin Llewelyn, MD         
Cambridge University Hospitals Recruiting
Cambridge, United Kingdom, CB2 0QQ
Contact: Estee Torok, MD         
Hull and East Yorkshire Hospitals Recruiting
Hull, United Kingdom, HU3 2JZ
Contact: Gavin Barlow, MD         
Royal Liverpool and Broadgreen Hospital Recruiting
Liverpool, United Kingdom, L7 8XP
Contact: Emmanuel Nsutebu, MD         
Royal Free Hospital Recruiting
London, United Kingdom, NW3 2QG
Contact: Susan Hopkins, MD         
Guy's and St Thomas' Recruiting
London, United Kingdom, SE1 7EH
Contact: Jonathan Edgeworth, MD         
Kings College Hospital Recruiting
London, United Kingdom, SE5 9RS
Contact: Dakshika Jeyaratnam, MD         
University College London Hospital Recruiting
London, United Kingdom, WC1E 6AG
Contact: Peter Wilson, MD         
Oxford University Hospitals Recruiting
Oxford, United Kingdom, OX3 9DU
Contact: Matthew Scarborough, MD         
Plymouth Hospitals Recruiting
Plymouth, United Kingdom, PL6 8DH
Contact: Robert Tilley, MD         
Portsmouth Hospitals Recruiting
Portsmouth, United Kingdom, PO3 6AD
Contact: Sarah Wyllie, MD         
Sponsors and Collaborators
University of Cologne
Investigators
Study Chair: Achim J Kaasch, MD University of Cologne
  More Information

Publications:
Responsible Party: Achim Kaasch, Dr. Achim Kaasch, University of Cologne
ClinicalTrials.gov Identifier: NCT02098850     History of Changes
Other Study ID Numbers: ISAC-01
First Submitted: March 25, 2014
First Posted: March 28, 2014
Last Update Posted: December 3, 2014
Last Verified: December 2014

Keywords provided by Achim Kaasch, University of Cologne:
Staphylococcus aureus
bloodstream infection
bacteremia

Additional relevant MeSH terms:
Bacteremia
Bacterial Infections
Sepsis
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes